Floatz logo

Dexasone

Angioimmunoblastic T-Cell Lymphoma

Ou Bai, MD/PHDSmall moleculePhase 2Active
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
81/ 100

Competitive context

51 Active assets in the Angioimmunoblastic T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Isocyclophosphamide
Shandong Provincial Hospital
Phase 4BBB
Azacitidine
National Cancer Institute (NCI)
Phase 4BB
Fludarabine
National Cancer Institute (NCI)
Phase 2BB
Adriamycin
City of Hope Medical Center
Phase 4BB
Prednisone
Shanghai Jiao Tong University School of Medicine
Phase 4BB

View all 50 →

Same molecule, other indications

Dexasone is also rated in:

chemotherapy-induced toxicityActive
A
Indicative · Phase 4
82 / 100
View asset →
adult acute lymphoblastic leukemiaActive
BBB
Indicative · Phase 4
79 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative · Phase 3
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →